摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2-amidino-1,2,3,4-tetrahydroisoquinolin-7-yloxymethyl)-1-(pyridin-4-yl)piperidine-4-carboxylic acid | 247131-06-2

中文名称
——
中文别名
——
英文名称
4-(2-amidino-1,2,3,4-tetrahydroisoquinolin-7-yloxymethyl)-1-(pyridin-4-yl)piperidine-4-carboxylic acid
英文别名
JTV-803 free base;4-[(2-carbamimidoyl-3,4-dihydro-1H-isoquinolin-7-yl)oxymethyl]-1-pyridin-4-ylpiperidine-4-carboxylic acid
4-(2-amidino-1,2,3,4-tetrahydroisoquinolin-7-yloxymethyl)-1-(pyridin-4-yl)piperidine-4-carboxylic acid化学式
CAS
247131-06-2
化学式
C22H27N5O3
mdl
——
分子量
409.488
InChiKey
MISBTXJXWSXZBF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    30
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    116
  • 氢给体数:
    3
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Amidine compounds
    摘要:
    该化合物的化学式为 [I],其中R1、R2和R3相同或不同,且均为氢原子,其中每个符号的定义如规范中所述,其盐或前药。本发明的化合物、其盐和前药可用作因子Xa抑制剂和血液凝固抑制剂,并可用于预防和/或治疗由血液凝固或血栓引起的疾病。
    公开号:
    US06562828B1
  • 作为产物:
    描述:
    1-(pyridin-4-yl)-4-(1,2,3,4-tetrahydroisoquinolin-7-yloxymethyl)piperidine-4-carboxylic acid ethyl ester 在 盐酸碳酸氢钠 作用下, 以 丙酮 为溶剂, 生成 4-(2-amidino-1,2,3,4-tetrahydroisoquinolin-7-yloxymethyl)-1-(pyridin-4-yl)piperidine-4-carboxylic acid
    参考文献:
    名称:
    Discovery of novel tetrahydroisoquinoline derivatives as potent and selective factor Xa inhibitors
    摘要:
    A series of novel 2,7-disubstituted tetrahydroisoquinoline derivatives were designed and synthesized. Among these derivatives, compounds I and 2 (JTV-803) exhibited potent inhibitory activity against FXa and good selectivity with respect to other serine proteases (thrombin, plasmin, and trypsin). In addition, compound 2 exhibited potent anti-FXa activity after intravenous and oral administration to cynomolgus monkey, and showed a dose-dependent antithrombotic effect in a rat model of venous thrombosis. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.10.033
点击查看最新优质反应信息

文献信息

  • Method For Improved Bioactivation Of Pharmaceuticals
    申请人:Clement Bernd
    公开号:US20120077876A1
    公开(公告)日:2012-03-29
    This invention relates to a prodrug comprising a partial structure having the general formula (I) or (II), where R 1 and R 2 are hydrogen, alkyl, or aryl radicals.
    这项发明涉及一种前药,其包含具有一般式(I)或(II)的部分结构,其中R1和R2为氢、烷基或芳基基团。
  • Amidine compounds
    申请人:Japan Tobacco Inc.
    公开号:US06562828B1
    公开(公告)日:2003-05-13
    A compound of the formula [I] wherein R1, R2 and R3 are the same or different and each is hydrogen atom, wherein each symbol is as defined in the specification, a salt thereof or a prodrug thereof. The compound of the present invention, a salt thereof and a prodrug thereof are useful as factor Xa inhibitor and blood coagulation inhibitor, and are useful for the prophylaxis and/or treatment of diseases caused by blood coagulation or thrombus.
    该化合物的化学式为 [I],其中R1、R2和R3相同或不同,且均为氢原子,其中每个符号的定义如规范中所述,其盐或前药。本发明的化合物、其盐和前药可用作因子Xa抑制剂和血液凝固抑制剂,并可用于预防和/或治疗由血液凝固或血栓引起的疾病。
  • AMIDINE COMPOUNDS
    申请人:Japan Tobacco Inc.
    公开号:EP1070714A1
    公开(公告)日:2001-01-24
    Compounds represented by general formula [I] or salts thereof or prodrugs of the same [I] wherein R1, R2 end R3 are the same or different and each represents hydrogen, hydroxy, lower alkyl or aryl; and R represents formulas (a), (b) and (c) (wherein each symbol has the meaning as defined in the specification). These compounds, salts thereof or prodrugs of the same are useful as factor Xa inhibitors and anticoagulants and usable in preventing and/or treating diseases caused by blood coagulation or thrombi.
    通式[I]代表的化合物或其盐类或其原药[I],其中R1、R2和R3是相同或不同的,各自代表氢、羟基、低级烷基或芳基;R代表式(a)、(b)和(c)(其中各符号具有说明书中定义的含义)。这些化合物、其盐类或其原药可作为 Xa 因子抑制剂和抗凝剂,用于预防和/或治疗由血液凝固或血栓引起的疾病。
  • Compositions and methods for cell transplantation
    申请人:UNIVERSITÉ CATHOLIQUE DE LOUVAIN
    公开号:US10478459B2
    公开(公告)日:2019-11-19
    The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition with procoagulant cells and at least one factor Xa inhibitor, preferably rivaroxaban, as well as at least one thrombin inhibitor, preferably bivalirudin.
    本发明涉及细胞移植的组合物和方法。特别是,本发明提供了一种含有促凝血细胞和至少一种Xa因子抑制剂(最好是利伐沙班)以及至少一种凝血酶抑制剂(最好是比伐卢定)的组合物。
  • VERFAHREN ZUR VERBESSERTEN BIOAKTIVIERUNG VON ARZNEISTOFFEN
    申请人:Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG
    公开号:EP2376074B1
    公开(公告)日:2019-03-13
查看更多